Bacterial Pathogenesis Laboratory, The Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia.
Vaccine. 2012 Mar 9;30(12):2197-205. doi: 10.1016/j.vaccine.2011.12.115. Epub 2012 Jan 20.
A major challenge for Streptococcus pyogenes vaccine development is the identification of epitopes that confer protection from infection by multiple S. pyogenes M-types. Here we have identified and characterised the distribution of common variant sequences from individual repeat units of the C-repeat region (CRR) of M-proteins representing 77 different M-types. Three polyvalent fusion vaccine candidates (SV1, SV2 and SV3) incorporating the most common variants were subsequently expressed and purified, and demonstrated to be alpha-helical by Circular Dichroism (CD), a secondary conformational characteristic of the CRR in the M-protein. Antibodies raised against each of these constructs recognise M-proteins that vary in their CRR, and bind to the surface of multiple S. pyogenes isolates. Antibodies raised against SV1, containing five variant sequences, also kill heterologous S. pyogenes isolates in in vitro bactericidal assays. Further structural characterisation of this construct demonstrated the conformation of SV1 was stable at different pHs, and thermal unfolding of SV1 is a reversible process. Our findings demonstrate that linkage of multiple variant sequences into a single recombinant construct overcomes the need to embed the variant sequences in foreign helix promoting flanking sequences for conformational stability, and demonstrates the viability of the polyvalent candidates as global S. pyogenes vaccine candidates.
链球菌疫苗开发的主要挑战是确定能够预防多种 A 群链球菌 M 型感染的表位。在这里,我们鉴定并描述了代表 77 种不同 M 型的 M 蛋白 C 重复区(CRR)的单个重复单元的常见变异序列的分布。随后表达和纯化了包含最常见变异的三种多价融合疫苗候选物(SV1、SV2 和 SV3),并通过圆二色性(CD)证明它们是α-螺旋,这是 M 蛋白 CRR 的二级构象特征。针对这些构建体中的每一个产生的抗体识别在其 CRR 中变化的 M 蛋白,并与多种 A 群链球菌分离株的表面结合。针对包含五个变异序列的 SV1 产生的抗体也能在体外杀菌测定中杀死异源 A 群链球菌分离株。对该构建体的进一步结构表征表明,SV1 的构象在不同 pH 值下稳定,并且 SV1 的热解折叠是一个可逆过程。我们的研究结果表明,将多个变异序列链接到单个重组构建体中克服了将变异序列嵌入促进构象稳定性的外源螺旋促进侧翼序列的需要,并证明了多价候选物作为全球 A 群链球菌疫苗候选物的可行性。